Production of extended-spectrum β-lactamases and the potential indirect pathogenic role of Prevotella isolates from the cystic fibrosis respiratory microbiota

International Journal of Antimicrobial Agents

Volumn 47, Issue 2, 2016, Pages 140-145

  Sherrard, Laura J ^a   McGrath, Stef J ^a   McIlreavey, Leanne ^a   Hatch, Joseph ^b   Wolfgang, Matthew C ^b   Muhlebach, Marianne S ^b   Gilpin, Deirdre F ^a   Elborn, J Stuart ^a,c   Tunney, Michael M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Anaerobes; Antibiotic resistance; Cystic fibrosis; Lactams

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; EXTENDED SPECTRUM BETA LACTAMASE; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DNA SEQUENCE; ENZYME SYNTHESIS; FEMALE; HUMAN; IMMUNE EVASION; IN VITRO STUDY; LUNG FIBROSIS; LUNG INFECTION; MALE; MICROFLORA; MINIMUM INHIBITORY CONCENTRATION; POLYMERASE CHAIN REACTION; PRESCRIPTION; PREVALENCE; PREVOTELLA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; SEQUENCE ANALYSIS; ADOLESCENT; AGED; CHILD; COMPLICATION; CYSTIC FIBROSIS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; RESPIRATORY TRACT INFECTION; SECRETION (PROCESS); VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CEFTAZIDIME; CHILD; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MIDDLE AGED; PREVOTELLA; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTIONS; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84956937624     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.12.004     Document Type: Article

References (29)

1. M.M. Tunney, T.R. Field, T.F. Moriarty, S. Patrick, G. Doering, M.S. Muhlebach, and et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis Am J Respir Crit Care Med 177 2008 995 1001
2. M.M. Tunney, G.G. Einarsson, L. Wei, M. Drain, E.R. Klem, C. Cardwell, and et al. The lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation Am J Respir Crit Care Med 18 2013 1118 1126
3. A.A. Fodor, E.R. Klem, D.F. Gilpin, J.S. Elborn, R.C. Boucher, M.M. Tunney, and et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations PLoS One 7 2012 e45001
4. M.M. Tunney, E.R. Klem, A.A. Fodor, D.F. Gilpin, T.F. Moriarty, S.J. McGrath, and et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis Thorax 66 2011 579 584
5. J.K. Harris, M.A. De Groote, S.D. Sagel, E.T. Zemanick, R. Kapsner, C. Penvari, and et al. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis Proc Natl Acad Sci U S A 104 2007 20529 20533
6. F. Bittar, H. Richet, J.C. Dubus, M. Reynaud-Gaubert, N. Stremler, J. Sarles, and et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients PLoS One 3 2008 e2908
7. J. Zhao, P.D. Schloss, L.M. Kalikin, L.A. Carmody, B.K. Foster, J.F. Petrosino, and et al. Decade-long bacterial community dynamics in cystic fibrosis airways Proc Natl Acad Sci USA 109 2012 5809 5814
8. Y.J. Huang, E. Kim, M.J. Cox, E.L. Brodie, R. Brown, J.P. Wiener-Kronish, and et al. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations OMICS 14 2010 9 59
9. L.J. Sherrard, K.A. Graham, S.J. McGrath, L. McIlreavey, J. Hatch, M.S. Muhlebach, and et al. Antibiotic resistance in Prevotella species isolated from patients with cystic fibrosis J Antimicrob Chemother 68 2013 2369 2374
10. C. Alauzet, H. Marchandin, and A. Lozniewski New insights into Prevotella diversity and medical microbiology Future Microbiol 5 2010 1695 1718
11. L.J. Sherrard, M.M. Tunney, and J.S. Elborn Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis Lancet 384 2014 703 713
12. K. Bush, and G.A. Jacoby Updated functional classification of β-lactamases Antimicrob Agents Chemother 54 2010 969 976
13. D.L. Paterson, W.C. Ko, A. Von Gottberg, J.M. Casellas, L. Mulazimoglu, K.P. Klugman, and et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory J Clin Microbiol 39 2001 2206 2212
14. D.L. Paterson, W.C. Ko, A. Von Gottberg, S. Mohapatra, J.M. Casellas, H. Goossens, and et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases Clin Infect Dis 39 2004 31 37
15. I. Brook β-Lactamase-producing bacteria in mixed infections Clin Microbiol Infect 10 2004 777 784
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-third Informational supplement. Document M100-S23. Wayne, PA: CLSI; 2013.
17. UK Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis. Report of the UK Cystic Fibrosis Trust Working Group. Bromley, UK: UK Cystic Fibrosis Trust; 2009.
18. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard - eighth edition. Document M11-A8. Wayne, PA: CLSI; 2012.
19. L.J. Sherrard, B. Schaible, K.A. Graham, S.J. McGrath, L. McIlreavey, J. Hatch, and et al. Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients J Antimicrob Chemother 69 2014 2690 2698
20. Clinical and Laboratory Standards Institute. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. Wayne, PA: CLSI; 1999.
21. T.F. Moriarty, J.C. McElnay, J.S. Elborn, and M.M. Tunney Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection Pediatr Pulmonol 42 2007 1008 1017
22. R.L. White, D.S. Burgess, M. Manduru, and J.A. Bosso Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test Antimicrob Agents Chemother 40 1996 1914 1918
23. H. Seifert, A. Dalhoff PRISMA Study Group German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study J Antimicrob Chemother 65 2010 2405 2410
24. F. Mory, J.P. Carlier, C. Alauzet, M. Thouvenin, H. Schuhmacher, and A. Lozniewski Bacteremia caused by a metronidazole-resistant Prevotella sp strain J Clin Microbiol 43 2005 5380 5383
25. I.N. Rocas, and J.F. Siqueira Jr. Antibiotic resistance genes in anaerobic bacteria isolated from primary dental root canal infections Anaerobe 18 2012 576 580
26. S.H. Jeong, I.K. Bae, J.H. Lee, S.G. Sohn, G.H. Kang, G.J. Jeon, and et al. Molecular characterization of extended-spectrum β-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli from a Korean nationwide survey J Clin Microbiol 42 2004 2902 2906
27. I. Madinier, T. Fosse, J. Giudicelli, and R. Labia Cloning and biochemical characterization of a class A β-lactamase from Prevotella intermedia Antimicrob Agents Chemother 45 2001 2386 2389
28. C. Giraud-Morin, I. Madinier, and T. Fosse Sequence analysis of cfxA2-like β-lactamases in Prevotella species J Antimicrob Chemother 51 2003 1293 1296
29. U. Stiefel, M.A. Tima, and M.M. Nerandzic Metallo-β-lactamase-producing Bacteroides species can shield other members of the gut microbiota from antibiotics Antimicrob Agents Chemother 59 2015 650 653